A citation-based method for searching scientific literature

Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma, Noriomi Matsumura, Kaoru Abiko, Tsukasa Baba, Ken Yamaguchi, Akihiko Ueda, Yuko Hosoe, Satoshi Morita, Masayuki Yokode, Akira Shimizu, Tasuku Honjo, Ikuo Konishi. J Clin Oncol 2015
Times Cited: 591







List of co-cited articles
728 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
150
32

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, Phyllis A Gimotty, Marco Massobrio, Giorgia Regnani, Antonis Makrigiannakis, Heidi Gray, Katia Schlienger, Michael N Liebman,[...]. N Engl J Med 2003
30

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, Karen Kelly, J Thaddeus Beck, Michael Gordon, Kathleen M Moore, Manish R Patel, Jorge Chaves, Haeseong Park, Alain C Mita,[...]. JAMA Oncol 2019
133
26


Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
Dmitriy Zamarin, Robert A Burger, Michael W Sill, Daniel J Powell, Heather A Lankes, Michael D Feldman, Oliver Zivanovic, Camille Gunderson, Emily Ko, Cara Mathews,[...]. J Clin Oncol 2020
55
32

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
16

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, Monica Mita, John W Moroney, Robert Holloway, Linda Van Le, Jasgit C Sachdev, Eloise Chapman-Davis, Gerardo Colon-Otero,[...]. JAMA Oncol 2019
125
16

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Andrea Varga, Sarina Piha-Paul, Patrick A Ott, Janice M Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, Daniela Matei. Gynecol Oncol 2019
78
19


Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Junzo Hamanishi, Masaki Mandai, Masashi Iwasaki, Taku Okazaki, Yoshimasa Tanaka, Ken Yamaguchi, Toshihiro Higuchi, Haruhiko Yagi, Kenji Takakura, Nagahiro Minato,[...]. Proc Natl Acad Sci U S A 2007
980
13


Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, Scott Rodig, Lauren L Ritterhouse, Joyce F Liu, Judy E Garber, Dipanjan Chowdhury, Catherine J Wu, Alan D D'Andrea,[...]. Oncotarget 2016
307
12

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
12

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
11

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Joyce F Liu, Christina Herold, Kathryn P Gray, Richard T Penson, Neil Horowitz, Panagiotis A Konstantinopoulos, Cesar M Castro, Sarah J Hill, Jennifer Curtis, Weixiu Luo,[...]. JAMA Oncol 2019
50
22

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
910
11

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi,[...]. N Engl J Med 2012
10

Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Katsutoshi Oda, Junzo Hamanishi, Koji Matsuo, Kosei Hasegawa. Gynecol Oncol 2018
47
21

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Eiichi Sato, Sara H Olson, Jiyoung Ahn, Brian Bundy, Hiroyoshi Nishikawa, Feng Qian, Achim A Jungbluth, Denise Frosina, Sacha Gnjatic, Christine Ambrosone,[...]. Proc Natl Acad Sci U S A 2005
10

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
Wei-Ting Hwang, Sarah F Adams, Emin Tahirovic, Ian S Hagemann, George Coukos. Gynecol Oncol 2012
348
9

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Bernard Escudier, David F McDermott, Saby George, Hans J Hammers, Sandhya Srinivas, Scott S Tykodi, Jeffrey A Sosman, Giuseppe Procopio, Elizabeth R Plimack,[...]. N Engl J Med 2015
9

ARID1A mutations in endometriosis-associated ovarian carcinomas.
Kimberly C Wiegand, Sohrab P Shah, Osama M Al-Agha, Yongjun Zhao, Kane Tse, Thomas Zeng, Janine Senz, Melissa K McConechy, Michael S Anglesio, Steve E Kalloger,[...]. N Engl J Med 2010
9

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, Linhua Zou, Xavier Alvarez, Pui Cheng, Peter Mottram, Melina Evdemon-Hogan, Jose R Conejo-Garcia, Lin Zhang, Matthew Burow,[...]. Nat Med 2004
9

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
743
9

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
Joyce F Liu, Michael Gordon, Jennifer Veneris, Fadi Braiteh, Ani Balmanoukian, Joseph Paul Eder, Ana Oaknin, Erika Hamilton, Yulei Wang, Indrani Sarkar,[...]. Gynecol Oncol 2019
37
24

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
899
8

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
8

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
8

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
8

Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha,[...]. N Engl J Med 2015
8

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Anniina Färkkilä, Doga C Gulhan, Julia Casado, Connor A Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro,[...]. Nat Commun 2020
50
16

Ovarian Cancer Immunotherapy: Turning up the Heat.
Eleonora Ghisoni, Martina Imbimbo, Stefan Zimmermann, Giorgio Valabrega. Int J Mol Sci 2019
56
14

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
283
8

Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.
Brian C Willis, Emily A Sloan, Kristen A Atkins, Mark H Stoler, Anne M Mills. Mod Pathol 2017
29
24

Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Ronald L Chandler, Jeffrey S Damrauer, Jesse R Raab, Jonathan C Schisler, Matthew D Wilkerson, John P Didion, Joshua Starmer, Daniel Serber, Della Yee, Jessie Xiong,[...]. Nat Commun 2015
156
7

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Toru Sugiyama, Aikou Okamoto, Takayuki Enomoto, Tetsutaro Hamano, Eriko Aotani, Yasuhisa Terao, Nao Suzuki, Mikio Mikami, Nobuo Yaegashi, Kiyoko Kato,[...]. J Clin Oncol 2016
72
9

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
7

Integrated genomic characterization of endometrial carcinoma.
Cyriac Kandoth, Nikolaus Schultz, Andrew D Cherniack, Rehan Akbani, Yuexin Liu, Hui Shen, A Gordon Robertson, Itai Pashtan, Ronglai Shen, Christopher C Benz,[...]. Nature 2013
7

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
7

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Vicky Makker, Drew Rasco, Nicholas J Vogelzang, Marcia S Brose, Allen L Cohn, James Mier, Christopher Di Simone, David M Hyman, Daniel E Stepan, Corina E Dutcus,[...]. Lancet Oncol 2019
180
7

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
N Colombo, C Sessa, A du Bois, J Ledermann, W G McCluggage, I McNeish, P Morice, S Pignata, I Ray-Coquard, I Vergote,[...]. Ann Oncol 2019
192
7

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
752
7

Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
Xia Yuan, Jing Zhang, Dan Li, Ye Mao, Fei Mo, Wei Du, Xuelei Ma. Gynecol Oncol 2017
90
7

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
7

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
7

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Siân Jones, Tian-Li Wang, Ie-Ming Shih, Tsui-Lien Mao, Kentaro Nakayama, Richard Roden, Ruth Glas, Dennis Slamon, Luis A Diaz, Bert Vogelstein,[...]. Science 2010
811
6

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
674
6

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Benjamin G Bitler, Katherine M Aird, Azat Garipov, Hua Li, Michael Amatangelo, Andrew V Kossenkov, David C Schultz, Qin Liu, Ie-Ming Shih, Jose R Conejo-Garcia,[...]. Nat Med 2015
351
6

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
6

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.
Brooke E Howitt, Kyle C Strickland, Lynette M Sholl, Scott Rodig, Lauren L Ritterhouse, Dipanjan Chowdhury, Alan D D'Andrea, Ursula A Matulonis, Panagiotis A Konstantinopoulos. Oncoimmunology 2017
51
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.